Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | FAAH | O00519 | 4/20 | 0.58 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.58 |
| ▸ | TERT | O14746 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | BLM | P54132 | 2/20 | 0.56 |
| ▸ | FABP4 | P15090 | 2/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.56 |
| ▸ | PPARG | P37231 | 2/20 | 0.56 |
| ▸ | PPARD | Q03181 | 2/20 | 0.56 |
| ▸ | PPARA | Q07869 | 2/20 | 0.56 |
| ▸ | GMNN | O75496 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL833160 | 1.00 | LMNA (0.68) | LMNAHSD17B10KMT2AMEN1ALDH1A1 | |
| SCHEMBL1302194 | 1.00 | LMNA (0.68) | LMNAHSD17B10KMT2AMEN1ALDH1A1 | |
| SCHEMBL5044800 | 1.00 | LMNA (0.68) | LMNAHSD17B10KMT2AMEN1ALDH1A1 | |
| SCHEMBL5361747 | 1.00 | LMNA (0.68) | LMNAHSD17B10KMT2AMEN1ALDH1A1 | |
| SCHEMBL22616793 | 1.00 | LMNA (0.68) | LMNAHSD17B10KMT2AMEN1ALDH1A1 | |
| SCHEMBL24450559 | 1.00 | LMNA (0.68) | LMNAHSD17B10KMT2AMEN1ALDH1A1 | |
| SCHEMBL5040020 | 1.00 | LMNA (0.68) | LMNAHSD17B10KMT2AMEN1ALDH1A1 | |
| SCHEMBL2933864 | 1.00 | LMNA (0.68) | LMNAHSD17B10KMT2AMEN1ALDH1A1 | |
| SCHEMBL21065749 | 1.00 | LMNA (0.68) | LMNAHSD17B10KMT2AMEN1ALDH1A1 | |
| SCHEMBL4881870 | 1.00 | LMNA (0.68) | LMNAHSD17B10KMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11856951-B2 | Method for managing resistance to insecticidal traits and chemicals using pheromones | PROVIVI, INC. (US) | 2024-01-02 | — | — | US | claimed |
| EP-1850670-A4 | FORMULATIONS USEFUL FOR THE TREATMENT OF VARICELLA ZOSTER VIRUS INFECTIONS AND METHODS FOR THE USE THEREOF | VERBISCAR ANTHONY J (US) | 2008-08-06 | — | — | EP | claimed |
| EP-1850670-A1 | FORMULATIONS USEFUL FOR THE TREATMENT OF VARICELLA ZOSTER VIRUS INFECTIONS AND METHODS FOR THE USE THEREOF | Verbiscar, Anthony, J. (US) | 2007-11-07 | — | — | EP | claimed |
| WO-2006112938-A1 | FORMULATIONS USEFUL FOR THE TREATMENT OF VARICELLA ZOSTER VIRUS INFECTIONS AND METHODS FOR THE USE THEREOF | VERBISCAR ANTHONY J (US) | 2006-10-26 | — | — | WO | claimed |
| US-20050203187-A1 | Formulations useful for the treatment of varicella zoster virus infections and methods for the use thereof | VERBISCAR ANTHONY J (US) | 2005-09-15 | — | — | US | claimed |
| EP-4648744-A1 | CONTROLLED RELEASE SEMI-SOLID EMULSION FORMULATIONS OF SEMIOCHEMICALS | Pheromones Biotech LLP (IN) | 2025-11-19 | — | — | EP | disclosed |
| EP-4646109-A2 | NATURAL LIPID PARTICLE FORMULATIONS FOR AGRICULTURAL APPLICATIONS | Invaio Sciences, Inc. (US) | 2025-11-12 | — | — | EP | disclosed |
| WO-2024168193-A2 | NATURAL LIPID PARTICLE FORMULATIONS FOR AGRICULTURAL APPLICATIONS | INVAIO SCIENCES, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-20240237642-A1 | CONTROLLED RELEASE SEMI-SOLID EMULSION FORMULATIONS OF SEMIOCHEMICALS | PHEROMONES BIOTECH LLP (IN) | 2024-07-18 | — | — | US | disclosed |
| WO-2024150040-A1 | CONTROLLED RELEASE SEMI-SOLID EMULSION FORMULATIONS OF SEMIOCHEMICALS | PHEROMONES BIOTECH LLP (IN) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024081627-A1 | STORAGE STABLE PHEROMONE COMPOSITIONS AND SYSTEMS | PROVIVI, INC. (US) | 2024-04-18 | — | — | WO | disclosed |
| US-11884940-B2 | Multi-substrate metabolism for improving biomass and lipid production | PROVIVI, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-9776179-B2 | Production of fatty olefin derivatives via olefin metathesis | PROVIVI, INC. (US) | 2017-10-03 | — | — | US | disclosed |
| WO-2017112887-A1 | METHOD FOR MANAGING RESISTANCE TO INSECTICIDAL TRAITS AND CHEMICALS USING PHEROMONES | PROVIVI, INC. (US) | 2017-06-29 | — | — | WO | disclosed |
| US-20170135343-A1 | AGRICULTURAL PHEROMONE COMPOSITIONS COMPRISING POSITIONAL ISOMERS | PROVIVI, INC. | 2017-05-18 | — | — | US | disclosed |
| US-20170137365-A1 | PRODUCTION OF FATTY OLEFIN DERIVATIVES VIA OLEFIN METATHESIS | PROVIVI, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| EP-1850670-A4 | FORMULATIONS USEFUL FOR THE TREATMENT OF VARICELLA ZOSTER VIRUS INFECTIONS AND METHODS FOR THE USE THEREOF | VERBISCAR ANTHONY J (US) | 2008-08-06 | — | — | EP | disclosed |
| EP-1850670-A1 | FORMULATIONS USEFUL FOR THE TREATMENT OF VARICELLA ZOSTER VIRUS INFECTIONS AND METHODS FOR THE USE THEREOF | Verbiscar, Anthony, J. (US) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006112938-A1 | FORMULATIONS USEFUL FOR THE TREATMENT OF VARICELLA ZOSTER VIRUS INFECTIONS AND METHODS FOR THE USE THEREOF | VERBISCAR ANTHONY J (US) | 2006-10-26 | — | — | WO | disclosed |
| US-20050203187-A1 | Formulations useful for the treatment of varicella zoster virus infections and methods for the use thereof | VERBISCAR ANTHONY J (US) | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137365-A1 | PRODUCTION OF FATTY OLEFIN DERIVATIVES VIA OLEFIN METATHESIS | SREBF1, F2, SREBF2 | LMNA 4620/4885HSD17B10 99/4885KMT2A 4144/4885 |
| US-20170135343-A1 | AGRICULTURAL PHEROMONE COMPOSITIONS COMPRISING POSITIONAL ISOMERS | PTMS, PTAR1, WAPL | LMNA 4409/4885HSD17B10 1417/4885KMT2A 3718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.